Heron Therapeutics Inc. (HRTX)
2.25
-0.06 (-2.60%)
At close: Mar 28, 2025, 3:59 PM
2.26
0.22%
After-hours: Mar 28, 2025, 04:05 PM EDT
-2.60% (1D)
| Bid | 2.22 |
| Market Cap | 343.5M |
| Revenue (ttm) | 152.92M |
| Net Income (ttm) | -13.51M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -25.06 |
| Forward PE | -72 |
| Analyst | Buy |
| Ask | 2.35 |
| Volume | 521,858 |
| Avg. Volume (20D) | 1,783,771 |
| Open | 2.33 |
| Previous Close | 2.31 |
| Day's Range | 2.23 - 2.33 |
| 52-Week Range | 1.04 - 3.93 |
| Beta | 1.55 |
About HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 1987
Employees 122
Stock Exchange NASDAQ
Ticker Symbol HRTX
Website https://www.herontx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 166.08% from the latest price.
Stock Forecasts1 month ago
+20.49%
Heron Therapeutics shares are trading higher follo...
Unlock content with
Pro Subscription
1 month ago
+19.88%
Heron Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
